or Try an Advanced Search...

    Technical Analysis for LTRN - Lantern Pharma Inc.

    Grade Last Price % Change Price Change
    D 6.68 3.09% 0.20
    LTRN closed up 0.93 percent on Wednesday, May 8, 2024, on 14 percent of normal volume.
    Earnings due: May 9
    *** please verify all earnings dates ***
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Up Down Up
    Historical LTRN trend table...
    Date Alert Name Type % Chg
    Wide Bands Range Expansion 3.09%
    50 DMA Resistance Bearish 4.05%
    Wide Bands Range Expansion 4.05%
    50 DMA Resistance Bearish -2.48%
    Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -2.48%
    Wide Bands Range Expansion -2.48%
    Up 3 Days in a Row Strength -2.48%
    Up 4 Days in a Row Strength -2.48%
    Up 5 Days in a Row Strength -2.48%
    Crossed Above 20 DMA Bullish 8.62%
    Older End-of-Day Signals for LTRN ...

       Recent Intraday Alerts

    Alert Time
    50 DMA Resistance about 1 hour ago
    Upper Bollinger Band Resistance about 1 hour ago
    60 Minute Opening Range Breakout about 2 hours ago
    Rose Above 50 DMA about 2 hours ago
    Down 2 % about 3 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    LTRN Chart by TradingView
    Basic chart:

    Profile

    Lantern Pharma, Inc. engages in the development of drugs through leveraging artificial intelligence, machine learning, and genomic data. Its portfolio includes LP-11, LP-300, and LP-184. The company was founded by Arun K. Asaithambi, Gregory T. Tobin, and Peter L. Nara on November 7, 2013 and is headquartered in Dallas, TX.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Artificial Intelligence Machine Learning Cybernetics Computational Neuroscience Pharma

    Is LTRN a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    May 6 Lantern Pharma and Oregon partner to develop cancer treatment
    May 6 Oregon Therapeutics & Lantern Pharma Launch Strategic AI Collaboration to Optimize Development of First-In-Class Drug Candidate XCE853 – A Potent Inhibitor of Cancer Metabolism
    May 2 Lantern Pharma to Report First Quarter 2024 Operating & Financial Results on May 9th, 2024 at 4:30 p.m. ET
    Apr 24 Lantern Pharma Launches "Webinar Wednesdays" Featuring World-Class Physician Scientists & Key Opinion Leaders Discussing Critical Areas of Oncology Drug Development
    Apr 22 Lantern Pharma Receives Regulatory Approval to Expand Harmonic™ Clinical Trial for Non-Small Cell Lung Cancer in Never-Smokers into Japan and Taiwan
    Mar 19 Lantern Pharma Inc. (NASDAQ:LTRN) Q4 2023 Earnings Call Transcript
    Mar 19 LTRN: 2023 Results
    Mar 19 Lantern Pharma Inc. (LTRN) Q4 2023 Earnings Call Transcript
    Mar 18 Lantern Pharma Inc Reports Progress and Financials for FY 2023
    Mar 18 Lantern Pharma GAAP EPS of -$0.39 beats by $0.01
    See more LTRN news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 11.99
    52 Week Low 2.38
    Average Volume 404,472
    200-Day Moving Average 4.71
    50-Day Moving Average 6.95
    20-Day Moving Average 5.84
    10-Day Moving Average 5.78
    Average True Range 0.77
    RSI (14) 51.92
    ADX 20.76
    +DI 26.35
    -DI 18.32
    Chandelier Exit (Long, 3 ATRs) 5.97
    Chandelier Exit (Short, 3 ATRs) 7.19
    Upper Bollinger Bands 6.87
    Lower Bollinger Band 4.80
    Percent B (%b) 0.81
    BandWidth 35.49
    MACD Line -0.23
    MACD Signal Line -0.39
    MACD Histogram 0.1604
    Fundamentals Value
    Market Cap 69.49 Million
    Num Shares 10.7 Million
    EPS -1.39
    Price-to-Earnings (P/E) Ratio -4.66
    Price-to-Sales 0.00
    Price-to-Book 0.98
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 7.41
    Resistance 3 (R3) 7.42 7.12 7.26
    Resistance 2 (R2) 7.12 6.88 7.12 7.20
    Resistance 1 (R1) 6.80 6.74 6.65 6.79 7.15
    Pivot Point 6.50 6.50 6.43 6.50 6.50
    Support 1 (S1) 6.18 6.26 6.03 6.17 5.81
    Support 2 (S2) 5.88 6.12 5.88 5.76
    Support 3 (S3) 5.56 5.88 5.71
    Support 4 (S4) 5.55